Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Strengthens Financial Position
Provides Additional Support for Completion of Phase 3 Trial and Submission of New Drug Application (NDA)
View HTML
Toggle Summary Evoke Reaches Study Enrollment Milestone Associated With Credit Facility
150 Patients Enrolled in Phase 3 Clinical Trial
View HTML
Toggle Summary U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001
States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs
View HTML
Toggle Summary Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001
SOLANA BEACH, Calif. , Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2015 Results
Enrolled 130 total subjects in Phase 3 clinical trial through end of July Recent FDA draft guidance of advice on Gastroparesis mirrors Evoke's Phase 3 clinical trial protocol design SOLANA BEACH, Calif. , Aug. 13, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2015 Financial Results
SOLANA BEACH, Calif. , July 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2015 on Thursday, August 13,
View HTML
Toggle Summary Evoke Pharma to Present at Cantor Fitzgerald Inaugural Healthcare Conference
SOLANA BEACH, Calif. , July 1, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, July 8, 2015 at 10:15 AM ET at the Cantor Fitzgerald Inaugural
View HTML
Toggle Summary Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis
Second Phase 2 Trial Demonstrates Effectiveness of Intranasal Metoclopramide Spray
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2015 Results
Company Begins Preparation for Commercialization of EVK-001
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2015 Financial Results
SOLANA BEACH, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter of 2015 on Thursday, May 14, 2015,
View HTML